Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ValEAR Trial: Valganciclovir for cCMV Infected Hearing Impaired Infants
NCT03107871Phase 2Terminated
- Start
- Aug 2018
- Primary completion
- Aug 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of valganciclovir in congenital cytomegalovirus infection (cCMV), sensorineural hearing loss (SNHL). Started Aug 2018; status: terminated.
02
Drugs
valganciclovir
03
Conditions
congenital cytomegalovirus infection (cCMV)sensorineural hearing loss (SNHL)
Beyond the preview
Go deeper on NCT03107871.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03107871.